Product Images Oxcarbazepine

This text provides results from a Tog-rank test, specifically the p-value which is 0.0001. There is also a table showing a time trial from Day 2 with the corresponding days from Day 1, as well as an observation in the Treatment Group relating to Oxcarbazeping.*

The text is a statistical analysis of the seizure rate between two groups, one that received oxcarbazepine treatment and another that received placebo. The log-rank test p-value was found to be 0.046, suggesting a statistically significant difference between the groups in terms of their seizure rates. The graph shows the number of days from the first dose to the first seizure, ranging from 0 to 140 days.*

This is a survival analysis result where a log-rank test was performed, resulting in a very low p-value of 0.0001. The graph shows the time to exit in days and indicates the treatment group (HIGH or LOW).*

This is a statistical analysis output showing the log-rank test results with a p-value of 0.0001. The remaining text is not readable and appears to be a combination of characters and symbols. Therefore, no additional useful information can be extracted from the text.*

This is a description of a prescription medication called PrecisionDose™ OXcarbazepine Oral Suspension. This medication comes in a bottle that delivers 5 mL of a solution containing 300 mg of the active ingredient, oxcarbazepine, which is used to treat seizures. The NDC (National Drug Code) for this medication is 68094-123-59. The manufacturer of the medication is Precision Dose, Inc. based in South Beloit, Illinois. The medication should be shaken well before use and stored at a temperature between 20°C and 25°C (68°F and 77°F). This medication is available by prescription only.*